Fig. 1: Characterization of anti-BCMA CAR-T cells.
From: Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
A BCMA CAR-T could kill the target cells at different ratios of effector:target cells, and killing of MM.1S cells was more efficient than that of Daudi cells, n = 3, **P < 0.01, ***P < 0.001, ****P < 0.0001. B Secretion of the cytokines IFN-γ and TNF-α during the killing process, n = 3, ****P < 0.0001. C Bioluminescence image analysis of B-NDG (NOD-PrkdcscidIL2rgtm1) mice with luciferase gene-transduced MM.1S cells (MM.1S-Luc) that received PBS vehicle control, control T cells, or BCMA CAR-T cells at a dose of 1 × 107 cells/mice in each experimental group at different time points after treatment. D CAR-T cells efficiently attenuated the tumor progression and significantly prolonged survival in mice.
